results from 110 subjects with cpp, 46 girls (41.8%) were considered as intervention and 64 (58.2%) as control groups. the mean age at initial visit was 7.46 ± 1.03 years. the bmi standard deviation scores in both groups was not significantly different at sixth and 12th months of treatment compared with baseline (p = 0.257 and p = 0.839, respectively). the prevalence of obesity was not signific...

background: determination of oocyte fertilization and embryo quality are one of the most important purposes in art cycles. follicular fluid provides an important microenvironment for development of oocytes and some biochemical characteristics of the follicular fluid, such as pregnancy-associated plasma protein-a (papp-a), may play an important role in prediction of success rate of art. objectiv...

Gonadotropin releasing hormone analogues (GnRHa) are often used to regress endometriosis implants and prevent premature luteinizing hormone surges in women undergoing controlled ovarian stimulation. In addition to GnRH central action, the expression of GnRH and receptors in the endometrium implies an autocrine/paracrine role for GnRH and an additional site of action for GnRHa. To further examin...

BACKGROUND Blood flow in the corpus luteum (CL) is closely related to luteal function. It is unclear how luteal blood flow is regulated. Standardized ovarian-stimulation protocol with a gonadotropin-releasing hormone agonist (GnRHa long protocol) causes luteal phase defect because it drastically suppresses serum LH levels. Examining luteal blood flow in the patient undergoing GnRHa long protoco...

Background Follicle stimulating hormone and testosterone stimulate Sertoli cells to support germ cell function and differentiation. During mini-puberty, when gonadotropin (GnRH) stimulates increases in plasma luteinizing hormone (LH) and testosterone levels, gonocytes are transformed into Ad spermatogonia. In cryptorchidism, impaired gonadotropin secretion during mini-puberty results in insuffi...

Gonadotropin-releasing hormone (GnRH) receptor is present in 80% of ovarian cancer, and numerous studies have provided evidence for a role of GnRH in cell proliferation. In this study, the effect of GnRH on the invasion potential of ovarian cancer cells was investigated. In vitro migration and cell invasion assays with the ovarian cancer cell lines Caov-3 and OVCAR-3 revealed the biphasic natur...

Recently, several new promising modifications have been introduced to clinical practice that may simplify and optimize IVF outcome. In the present opinion paper we present a simplified approach to controlled ovarian hyperstimulation protocol (COH), which combines the benefits of the ultrashort flare GnRH agonist/GnRH antagonist protocol and the personalized tailored mode and timing of ovulation...

Central precocious puberty (CPP) is a diagnosis that pediatric endocrinologists worldwide increasingly make in girls of age 6-8 years and is mostly idiopathic. Part of the reason for increasing referral and diagnosis is the perception among the doctors as well as the patients that treatment of CPP with long-acting gonadotropin-releasing hormon analogues (GnRHa) promote height of the child. Alth...

We report on GH (0.5 IU or 0.17 mg/kg/week) and GnRH analog (GnRHa, 60 pg/kg, every 4 weeks) therapy in SHOX haploinsufficiency. Case 1 was a 46,XY boy with microdeletion of the Y chromosomal pseudoautosomal region. At 7 years of age, he exhibited short stature (-3.9 SD) with a reduced growth rate (3.8 cm/year), short 4th metacarpals, and mild Madelung deformity. GH therapy resulted in a marked...

The effectiveness of two kinds of dopamine antagonist (DA), metoclopramide (Met) and domperidone (Dom) combined with the gonadotropin releasing hormone analogue (D-Ala6, Des Gly10 ethylamide) GnRHa was assayed on the ovulation success, latency period, ovulation index (OI) and fertilization success of kutum, Rutilus frisii kutum (Kamenskii, 1901). Brood fish were injected intra-peritoneally as f...